DGAP-News: 4TEEN4's first-in-class therapeutic antibody Procizumab restores heart function in life-threatening cardiac depression induced by sepsis
The study data (1) from the team lead by Prof. Alexandre Mebazaa have shown that high DPP3 blood values are associated with decreased heart function in a preclinical sepsis model.
DGAP-News: 4TEEN4 Pharmaceuticals GmbH / Key word(s): Scientific publication/Study results 4TEEN4's first-in-class therapeutic antibody Procizumab restores heart function in life-threatening cardiac depression induced by sepsis 16.09.2020 / 10:00 The issuer is solely responsible for the content of this announcement.
Hennigsdorf/ Berlin, Germany, September 16, 2020 - 4TEEN4 Pharmaceuticals GmbH ("4TEEN4") announces data on the efficacy of its lead product, Procizumab, that promptly restored cardiac dysfunction in a preclinical sepsis model by inhibiting the cardiac depressant factor DPP3. The current findings indicate that DPP3 plays an important role in septic cardiomyopathy. Sepsis is a dysregulated host response to an infection that ultimately leads to organ dysfunction.
16.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
1132037 16.09.2020